[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-406824-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-406824-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","adherence-to-antiviral-treatment-among-people-living-with-chronic-hepatitis-b-a-global-survey","Adherence to antiviral treatment among people living with chronic hepatitis B: A global survey","","Current antiviral treatment for chronic hepatitis B can suppress viral replication and lower the risk of cirrhosis and liver cancer, yet it requires lifelong daily medication and long-term adherence remains a common concern. A global anonymous online survey assessed factors linked to adherence to hepatitis B oral antivirals among adults living with chronic hepatitis B, using a treated subsample of 614 individuals. Results showed 81% high adherence, while lower adherence was associated with African/African American identification and challenges in affordability, healthcare acceptability, and physical functioning.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/adherence-to-antiviral-treatment-among-people-living-with-chronic-hepatitis-b-a-global-survey/406824/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/adherence-to-antiviral-treatment-among-people-living-with-chronic-hepatitis-b-a-global-survey/406824.png","ImageObject",300,407,{"name":42,"@type":43},"Muffet","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-28",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s main objective?","Question",{"text":63,"@type":64},"To evaluate factors associated with adherence to hepatitis B oral antiviral treatment among adults living with chronic hepatitis B.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was adherence assessed and who participated?",{"text":68,"@type":64},"The study used a global anonymous online survey, and analysis included a subsample of 614 individuals who reported being on hepatitis B treatment.",{"name":70,"@type":61,"acceptedAnswer":71},"What factors were linked to lower adherence?",{"text":72,"@type":64},"Lower adherence was observed among African/African American participants and among those reporting challenges related to affordability, healthcare service acceptability, and physical functioning.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},406824,1790687048,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":55,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":113,"preview_page_count":4},962090768927,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","| W | J | V | World Journal of\u003Cbr>Virology |\n| --- | --- | --- | --- |\n\nSubmit a Manuscript: [https://www.f6publishing.com](https://www.f6publishing.com) World J Virol 2025 December 25; 14(4): 110951  \nDOI: 10.5501/wjv.v14.i4.110951 ISSN 2220-3249 (online)  \nORIGINAL ARTICLE  \nObservational Study  \nAdherence to antiviral treatment among people living with chronic hepatitis B: A global survey  \nSuzanne J Block, Yasmin Ibrahim, Chari Cohen  \nSpecialty type: Virology  \nProvenance and peer review:  \nInvited article; Externally peer reviewed.  \nPeer-review model: Single blind  \nPeer-review report’s classification Scientific Quality: Grade B, Grade B, Grade B  \nNovelty: Grade B, Grade B, Grade B  \nCreativity or Innovation: Grade B, Grade B, Grade B  \nScientific Significance: Grade A, Grade B, Grade B  \nP-Reviewer: Alshammary RAA, PhD, Iraq; Chen LQ, PhD, Associate Professor, Postdoctoral Fellow, China  \nReceived: June 19, 2025  \nRevised: September 12, 2025  \nAccepted: December 2, 2025  \nPublished online: December 25, 2025  \nProcessing time: 189 Days and 13.7 Hours  \nSuzanne J Block, Department of Health, Behavior and Society Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States  \nYasmin Ibrahim, Chari Cohen, Hepatitis B Foundation, Doylestown, PA 18902, United States  \nCorresponding author: Suzanne J Block, RN, BSN, MPH, Department of Health, Behavior and Society Johns Hopkins Bloomberg School of Public Health, 615 N Wolfe Street, Baltimore, MD 21205, [United States.](United States. sblock8@jhmi.edu)[ sblock8@jhmi.edu](United States. sblock8@jhmi.edu)  \nAbstract  \nBACKGROUND  \nCurrent antiviral treatment for chronic hepatitis B can suppress viral replication and reduce the risk of cirrhosis and liver cancer. It requires lifelong daily medication, and long-term adherence is often cited as a concern when initiating treatment. Hepatitis B treatment adherence in the context of the patient’s medical and life experiences remains underexplored.  \nAIM  \nTo evaluate factors associated with adherence to hepatitis B oral antiviral treatment.  \nMETHODS  \nA global online survey was administered anonymously to adults (aged 18 years or older) living with chronic hepatitis B. A subsample of 614 individuals who reported being on hepatitis B treatment was included in the analysis. Indices for treatment affordability, healthcare service acceptability, and individual physical, psychological, and emotional functioning were constructed (Cronbach’s alpha = 0.71-0.83). Data analysis was conducted using Stata/BE 17.0.  \nRESULTS  \nOverall, 81% of respondents reported high adherence to hepatitis B treatment. Lower adherence was observed among individuals who identified as African or African American (P = 0.008). Among participants with low adherence, 60% cited affordability as a challenge (P = 0.068), 53% identified healthcare service acceptability as a challenge (P = 0.04), 79% described physical functioning as a challenge (P = 0.002), and 40.5% reported difficulties with psychological functioning (P = 0.55) .  \n WJV  [https://www.wjgnet.com](https://www.wjgnet.com) 1 December 25, 2025  Volume 14  Issue 4   \nBlock SJ et al. Global study on hepatitis B treatment adherence  \nCONCLUSION  \nFindings demonstrate high treatment adherence, although access to and acceptability of healthcare services, as well as an individual’s physical functioning challenges, appear to be related to low adherence.  \nKey Words: Chronic hepatitis B; Adherence; Antiviral treatment; Accessibility; Affordability  \n©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.  \nCore Tip: As we work towards global hepatitis B elimination, it is essential to understand how individuals’ medical and psychosocial dimensions of care influence treatment adherence. Overall findings from this study demonstrate high treatment adherence among participants living with hepatitis B. However, access to and acceptability of healthcare services, as we","cbCaiiosxXkk2vj1","https://ap.wps.com/l/cbCaiiosxXkk2vj1","pdf",462392,"English","# Abstract\n## Background\n## Aim\n## Methods\n## Results\n## Conclusion\n## Key Words\n## Core Tip","[{\"question\":\"What was the study’s main objective?\",\"answer\":\"To evaluate factors associated with adherence to hepatitis B oral antiviral treatment among adults living with chronic hepatitis B.\"},{\"question\":\"How was adherence assessed and who participated?\",\"answer\":\"The study used a global anonymous online survey, and analysis included a subsample of 614 individuals who reported being on hepatitis B treatment.\"},{\"question\":\"What factors were linked to lower adherence?\",\"answer\":\"Lower adherence was observed among African/African American participants and among those reporting challenges related to affordability, healthcare service acceptability, and physical functioning.\"}]","Adherence to antiviral treatment among people living with chronic hepatitis B: A global survey | PDF",1790568206]